Outcome of PTLD in renal and liver allograft recipients.
Gerstenkorn
C
C
Department of Transplant Surgery, The Medical School, University of Newcastle, Newcastle upon Tyne, United Kingdom.
Jackson
G
G
Di Franco
F
F
Thomusch
O
O
Talbot
D
D
D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis / Q000503:physiopathology; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology*; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology*; D008223:Lymphoma / Q000453:epidemiology* / Q000401:mortality / Q000503:physiopathology; D008232:Lymphoproliferative Disorders / Q000453:epidemiology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000503:physiopathology*; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents